Electrical Maintenance
GBE Group provide full-time employees for...
Funding and Investments to Improve Accessibility to Healthcare Services Driving Market’s Growth
Meticulous Research®—a leading market research company, published a research report titled, ‘Middle East & Africa Molecular Diagnostics Market by Offering (Reagents, Kits, Systems, Software) Test Type (Lab, PoC) Technology (PCR, ISH, INAAT, Sequencing, Microarray) Application (Influenza, HPV, Oncology, Gene Testing) End User - Forecast to 2031’According to this latest publication from Meticulous Research®, the Middle East & Africa molecular diagnostics market is projected to reach $1.16 billion by 2031, at a CAGR of 5.4% from 2024 to 2031. The growth of the Middle East & Africa molecular diagnostics market is driven by factors such as the rising prevalence of communicable and non-communicable diseases, technological advancements in molecular diagnostics, increasing investments and funding aimed at enhancing healthcare systems in the Middle East & Africa, and the rising healthcare expenditure in the region. However, inconsistencies in medical device regulations across the Middle East & Africa and the high costs of molecular diagnostic tests restrain the market’s growth.
Download Sample Report : https://www.meticulousresearch.com/download-sample-report/cp_id=5791
Key Findings of the Middle East & Africa Molecular Diagnostics Market Study:
The Reagents & Kits Segment is Expected to Account for the Largest Share of the Market in 2024
Among the offerings studied in this report, in 2024, the reagents & kits segment is expected to account for the largest share of the market. Molecular diagnostic kits are widely used by healthcare professionals in hospitals, clinics, and diagnostic laboratories to diagnose and manage various communicable & non-communicable diseases. Recurrent use of assays & kits in the detection of various diseases through molecular diagnostics, the proliferation of new products in the market, and technological advancements in molecular techniques contribute to the large market share of this segment. Partnerships, collaborations, and agreements among the players and other industry stakeholders are also positively impacting the market. In April 2023, Thermo Fisher Scientific, Inc. (U.S.) partnered with ALPCO Diagnostics (Czech Republic) to introduce 37 CE-IVD molecular assays to the market. One such assay is the TaqPath Menu| GeneProof PCR Kit, which can be used on a wide range of qPCR instruments. This kit facilitates the detection of various genetic diseases and pathogens, including STDs, respiratory infections, and bloodborne infections. These assays enable laboratories to conduct tests more rapidly and reduce the need for frequent instrument changes, enhancing efficiency. The tests are slated to be launched in regions such as the Middle East, Africa, Latin America, Asia, and select parts of Europe throughout 2024.
Browse in depth @ https://www.meticulousresearch.com/product/middle-east-and-africa-molecular-diagnostics-market-5791
The Laboratory Tests Segment is Expected to Account for the Largest Share of the Market in 2024
Among the test types studied in this report, in 2024, the laboratory tests segment is expected to account for the largest share of the market. Laboratory tests have traditionally been conducted in hospitals and diagnostic centers. The laboratory testing approach for molecular diagnostics offers numerous advantages over other methods. It is characterized by higher accuracy and reliability compared to point-of-care testing, which contributes to its greater adoption in laboratory settings compared to PoC tests.
The Polymerase Chain Reaction (PCR) Segment is Expected to Account for the Largest Share of the Market in 2024
Among the technologies studied in this report, in 2024, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the molecular diagnostics market in the Middle East & Africa. PCR enables the rapid amplification of a specific segment of DNA, making it a crucial technology that aids in disease diagnosis. Due to its effectiveness in detecting low-number targets and its cost-effectiveness compared to other technologies like sequencing, there is significant demand for PCR tests, further bolstering the segment's largest share. For instance, in February 2023, Dubai, UAE, hosted the "Medlab Middle East 2023" exhibition and conference, a 4-day event showcasing the latest products and technologies in laboratory management and diagnostics, including PCR. Such exhibitions and conferences play a crucial role in increasing awareness of advanced technologies and instrumentation.
Request Free Sample Report: https://www.meticulousresearch.com/request-sample-report/cp_id=5791
The Infectious Disease Segment is Expected to Account for the Largest Share of the Market in 2024
Based on application, in 2024, the infectious disease segment is expected to account for the largest share of the molecular diagnostics market in the Middle East & Africa. The large market share of this segment can be attributed to the growing incidence of infectious diseases and increased funding for infectious disease diagnostic research activities. The availability of funding specifically allocated for infectious disease research contributes to the growth of this segment. For instance, in April 2021, the Jameel Fund for Infectious Disease Research and Innovation announced a research fund aimed at supporting collaborative research between King Abdulaziz University (KAU) in Saudi Arabia and Imperial College London in the U.K. Under this initiative, grants totaling USD 500,000 were provided, equally distributed between both universities to support research projects spanning three to six months in duration.
Quick Buy @ https://www.meticulousresearch.com/Checkout/82693854
Key Players:
The key players profiled in the Middle East & Africa molecular diagnostics market report are AstraGene LLC (U.A.E.), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson and Company (U.S.), Illumina, Inc. (U.S.), AstraZeneca Gulf FZ LLC (Dubai), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), Abbott Laboratories (U.S), and Agilent Technologies, Inc. (U.S.).
Contact Us:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Please login to comment on this Post